| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.853 | 0.003 | 0.86 | Immunosuppressant | 0.86 0.003 DBMET03096 | DBMET03096 | |
| 0.724 | 0.005 | 0.724 | 5 Hydroxytryptamine release stimulant | 0.199 0.122 DBMET03096 | ||
| 0.698 | 0.001 | 0.963 | Sphingosine 1-phosphate receptor 3 agonist | 0.963 0.001 DBMET03096 | DBMET03096 | |
| 0.675 | 0.002 | 0.911 | Sphingosine 1-phosphate receptor 2 agonist | 0.911 0.001 DBMET03096 | DBMET03096 | |
| 0.662 | 0.011 | 0.662 | Cholesterol antagonist | 0.475 0.036 DBMET03096 | ||
| 0.636 | 0.009 | 0.689 | Immunomodulator | 0.689 0.005 DBMET03096 | DBMET03096 | |
| 0.6 | 0.002 | 0.867 | Sphingosine 1-phosphate receptor 5 agonist | 0.867 0.001 DBMET03096 | DBMET03096 | |
| 0.591 | 0.002 | 0.969 | Sphingosine 1-phosphate receptor 4 antagonist | 0.969 0.001 DBMET03096 | DBMET03096 | |
| 0.585 | 0.013 | 0.585 | 5 Hydroxytryptamine release inhibitor | 0.244 0.236 DBMET03096 | ||
| 0.572 | 0.004 | 0.822 | Phospholipase C inhibitor | 0.822 0.002 DBMET03096 | DBMET03096 | |
| 0.559 | 0.004 | 0.559 | Growth hormone agonist | 0.413 0.014 DBMET03096 | ||
| 0.504 | 0.001 | 0.504 | Sphingosine kinase inhibitor | 0.393 0.002 DBMET03096 | ||
| 0.491 | 0.002 | 0.966 | Sphingosine 1-phosphate receptor 4 agonist | 0.966 0.001 DBMET03096 | DBMET03096 | |
| 0.469 | 0.004 | 0.469 | Tyrosine 3 hydroxylase inhibitor | 0.238 0.08 DBMET03096 | ||
| 0.447 | 0.001 | 0.447 | Sphingosine kinase 1 inhibitor | 0.358 0.002 DBMET03096 | ||
| 0.439 | 0.002 | 0.861 | Sphingosine 1-phosphate receptor 2 antagonist | 0.861 0.001 DBMET03096 | DBMET03096 | |
| 0.439 | 0.014 | 0.439 | Interleukin agonist | 0.41 0.017 DBMET03096 | ||
| 0.435 | 0.013 | 0.676 | Anesthetic general | 0.676 0.004 DBMET03096 | DBMET03096 | |
| 0.459 | 0.046 | 0.459 | Histamine release inhibitor | |||
| 0.416 | 0.006 | 0.416 | Peptidyltransferase inhibitor | 0.326 0.017 DBMET03096 | ||
| 0.401 | 0.001 | 0.952 | Sphingosine 1-phosphate receptor 5 antagonist | 0.952 0 DBMET03096 | DBMET03096 | |
| 0.376 | 0.001 | 0.396 | Sphingosine kinase 2 inhibitor | 0.396 0.001 DBMET03096 | DBMET03096 | |
| 0.408 | 0.046 | 0.408 | Aldehyde oxidase inhibitor | |||
| 0.38 | 0.018 | 0.38 | 5 Hydroxytryptamine uptake stimulant | |||
| 0.388 | 0.029 | 0.388 | Superoxide dismutase inhibitor | |||
| 0.341 | 0.004 | 0.341 | Phenylalanine 4-hydroxylase inhibitor | 0.074 0.042 DBMET03096 | ||
| 0.333 | 0.002 | 0.851 | Sphingosine 1-phosphate receptor 3 antagonist | 0.851 0.001 DBMET03096 | DBMET03096 | |
| 0.334 | 0.002 | 0.815 | Sphingosine 1-phosphate receptor agonist | 0.815 0.001 DBMET03096 | DBMET03096 | |
| 0.357 | 0.027 | 0.357 | Peroxidase inhibitor | |||
| 0.374 | 0.045 | 0.374 | Vasodilator, coronary | 0.246 0.138 DBMET03096 | ||
| 0.367 | 0.038 | 0.367 | Interleukin 2 agonist | 0.241 0.129 DBMET03096 | ||
| 0.32 | 0.003 | 0.95 | Sphingosine 1-phosphate receptor antagonist | 0.95 0.001 DBMET03096 | DBMET03096 | |
| 0.319 | 0.002 | 0.79 | Sphingosine 1-phosphate receptor 1 agonist | 0.79 0.001 DBMET03096 | DBMET03096 | |
| 0.347 | 0.038 | 0.347 | Hypoglycemic | |||
| 0.307 | 0.005 | 0.307 | ABCA1 expression enhancer | 0.122 0.029 DBMET03096 | ||
| 0.362 | 0.06 | 0.534 | Antithrombotic | 0.534 0.025 DBMET03096 | DBMET03096 | |
| 0.329 | 0.036 | 0.561 | Psychostimulant | 0.561 0.007 DBMET03096 | DBMET03096 | |
| 0.402 | 0.11 | 0.451 | Caspase 9 stimulant | 0.451 0.083 DBMET03096 | DBMET03096 | |
| 0.294 | 0.004 | 0.294 | Creatine kinase inhibitor | 0.173 0.016 DBMET03096 | ||
| 0.352 | 0.064 | 0.497 | Immunostimulant | 0.497 0.029 DBMET03096 | DBMET03096 | |
| 0.303 | 0.017 | 0.303 | Neurotrophic factor enhancer | 0.158 0.126 DBMET03096 | ||
| 0.38 | 0.095 | 0.38 | Calcium channel L-type activator | |||
| 0.294 | 0.012 | 0.294 | Succinate dehydrogenase inhibitor | 0.146 0.119 DBMET03096 | ||
| 0.413 | 0.131 | 0.413 | Antiinflammatory | 0.279 0.235 DBMET03096 | ||
| 0.275 | 0.003 | 0.908 | Sphingosine 1-phosphate receptor 1 antagonist | 0.908 0.001 DBMET03096 | DBMET03096 | |
| 0.32 | 0.05 | 0.32 | DNA damaging | 0.188 0.126 DBMET03096 | ||
| 0.276 | 0.014 | 0.475 | Aldehyde dehydrogenase inhibitor | 0.475 0.005 DBMET03096 | DBMET03096 | |
| 0.269 | 0.011 | 0.269 | Ferrochelatase inhibitor | |||
| 0.263 | 0.007 | 0.471 | Phosphofructokinase-1 inhibitor | 0.471 0.002 DBMET03096 | DBMET03096 | |
| 0.316 | 0.064 | 0.316 | Spasmolytic | 0.241 0.095 DBMET03096 | ||
| 0.313 | 0.067 | 0.313 | Sodium/bile acid cotransporter inhibitor | |||
| 0.29 | 0.047 | 0.44 | DNA synthesis inhibitor | 0.44 0.018 DBMET03096 | DBMET03096 | |
| 0.245 | 0.008 | 0.349 | Alcohol dehydrogenase inhibitor | 0.349 0.004 DBMET03096 | DBMET03096 | |
| 0.251 | 0.023 | 0.251 | Alpha-N-acetylglucosaminidase inhibitor | |||
| 0.244 | 0.025 | 0.383 | Phospholipase A2 inhibitor | 0.383 0.005 DBMET03096 | DBMET03096 | |
| 0.272 | 0.06 | 0.304 | Angiogenesis stimulant | 0.304 0.048 DBMET03096 | DBMET03096 | |
| 0.304 | 0.095 | 0.304 | Vasodilator, peripheral | |||
| 0.243 | 0.039 | 0.243 | Insulin sensitizer | |||
| 0.265 | 0.063 | 0.265 | Gastrin inhibitor | |||
| 0.219 | 0.017 | 0.219 | Aminopeptidase B inhibitor | 0.157 0.035 DBMET03096 | ||
| 0.224 | 0.022 | 0.425 | DNA polymerase I inhibitor | 0.425 0.005 DBMET03096 | DBMET03096 | |
| 0.2 | 0.005 | 0.228 | Ornithine decarboxylase inhibitor | 0.228 0.004 DBMET03096 | DBMET03096 | |
| 0.201 | 0.007 | 0.405 | Ornithine carbamoyltransferase inhibitor | 0.405 0.003 DBMET03096 | DBMET03096 | |
| 0.212 | 0.023 | 0.226 | Arachidonic acid antagonist | 0.226 0.014 DBMET03096 | DBMET03096 | |
| 0.269 | 0.08 | 0.269 | Insulysin inhibitor | |||
| 0.222 | 0.034 | 0.316 | Protein kinase stimulant | 0.316 0.015 DBMET03096 | DBMET03096 | |
| 0.198 | 0.012 | 0.265 | Vanilloid 1 agonist | 0.265 0.005 DBMET03096 | DBMET03096 | |
| 0.296 | 0.113 | 0.296 | Toll-Like receptor agonist | |||
| 0.189 | 0.008 | 0.189 | Glutamate decarboxylase inhibitor | 0.103 0.028 DBMET03096 | ||
| 0.188 | 0.009 | 0.236 | DOPA decarboxylase inhibitor | 0.236 0.004 DBMET03096 | DBMET03096 | |
| 0.196 | 0.016 | 0.376 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.376 0.004 DBMET03096 | DBMET03096 | |
| 0.185 | 0.008 | 0.362 | Carbamoyl phosphate synthetase inhibitor | 0.362 0.004 DBMET03096 | DBMET03096 | |
| 0.179 | 0.003 | 0.179 | Mannosidase inhibitor | 0.063 0.015 DBMET03096 | ||
| 0.189 | 0.015 | 0.189 | Photosensitizer | |||
| 0.19 | 0.018 | 0.196 | Adenylate cyclase stimulant | 0.196 0.015 DBMET03096 | DBMET03096 | |
| 0.184 | 0.013 | 0.332 | Sphingomyelinase inhibitor | 0.332 0.003 DBMET03096 | DBMET03096 | |
| 0.178 | 0.008 | 0.178 | Ca2+-transporting ATPase inhibitor | 0.133 0.104 DBMET03096 | ||
| 0.202 | 0.033 | 0.202 | Neurotensin receptor agonist | |||
| 0.174 | 0.008 | 0.174 | Interferon agonist | 0.153 0.01 DBMET03096 | ||
| 0.168 | 0.004 | 0.168 | Growth hormone releasing factor agonist | 0.05 0.013 DBMET03096 | ||
| 0.198 | 0.035 | 0.198 | Nav1.2 sodium channel blocker | |||
| 0.2 | 0.041 | 0.2 | Melanin inhibitor | 0.176 0.055 DBMET03096 | ||
| 0.187 | 0.03 | 0.263 | Toll-Like receptor 2 antagonist | 0.263 0.007 DBMET03096 | DBMET03096 | |
| 0.274 | 0.119 | 0.321 | Calcium channel activator | 0.321 0.072 DBMET03096 | DBMET03096 | |
| 0.186 | 0.035 | 0.186 | Neurotrophic factor | 0.15 0.059 DBMET03096 | ||
| 0.151 | 0.004 | 0.525 | Glutamate (mGluR6) antagonist | 0.525 0.001 DBMET03096 | DBMET03096 | |
| 0.151 | 0.004 | 0.151 | Alpha-mannosidase inhibitor | 0.068 0.018 DBMET03096 | ||
| 0.168 | 0.022 | 0.168 | Catalase inhibitor | |||
| 0.167 | 0.021 | 0.346 | Adenylate kinase inhibitor | 0.346 0.005 DBMET03096 | DBMET03096 | |
| 0.172 | 0.027 | 0.172 | GABA C receptor agonist | |||
| 0.192 | 0.047 | 0.192 | Diuretic | |||
| 0.154 | 0.01 | 0.154 | Alcohol oxidase inhibitor | |||
| 0.177 | 0.034 | 0.269 | Alkylator | 0.269 0.015 DBMET03096 | DBMET03096 | |
| 0.158 | 0.019 | 0.158 | Prolactin inhibitor | |||
| 0.156 | 0.018 | 0.156 | Electron transport complex I inhibitor | |||
| 0.156 | 0.018 | 0.396 | Triose-phosphate isomerase inhibitor | 0.396 0.003 DBMET03096 | DBMET03096 | |
| 0.171 | 0.034 | 0.171 | Cathepsin H inhibitor | |||
| 0.151 | 0.014 | 0.151 | Adrenaline agonist | |||
| 0.271 | 0.137 | 0.271 | GABA C receptor rho-3 antagonist | |||
| 0.159 | 0.025 | 0.159 | GABA C receptor antagonist | 0.121 0.051 DBMET03096 | ||
| 0.139 | 0.007 | 0.139 | Beta adrenoreceptor antagonist | |||
| 0.144 | 0.014 | 0.144 | Aminopeptidase I inhibitor | 0.101 0.027 DBMET03096 | ||
| 0.151 | 0.022 | 0.151 | Nitric-oxide synthase inhibitor | |||
| 0.132 | 0.005 | 0.132 | Interferon inducer | |||
| 0.17 | 0.046 | 0.461 | Bone formation stimulant | 0.461 0.007 DBMET03096 | DBMET03096 | |
| 0.165 | 0.042 | 0.165 | Monophenol monooxygenase inhibitor | |||
| 0.128 | 0.006 | 0.128 | Beta 1 adrenoreceptor antagonist | |||
| 0.127 | 0.012 | 0.218 | Acyl-CoA dehydrogenase inhibitor | 0.218 0.004 DBMET03096 | DBMET03096 | |
| 0.171 | 0.056 | 0.171 | Interferon gamma antagonist | |||
| 0.133 | 0.02 | 0.133 | Lanosterol 14 alpha demethylase inhibitor | |||
| 0.245 | 0.131 | 0.245 | Transcription factor NF kappa B inhibitor | |||
| 0.204 | 0.093 | 0.395 | RNA-directed DNA polymerase inhibitor | 0.395 0.019 DBMET03096 | DBMET03096 | |
| 0.114 | 0.005 | 0.114 | GHS receptor agonist | 0.041 0.033 DBMET03096 | ||
| 0.121 | 0.012 | 0.121 | Glycine receptor agonist | |||
| 0.113 | 0.004 | 0.113 | Growth hormone release promoting | 0.024 0.012 DBMET03096 | ||
| 0.153 | 0.047 | 0.153 | Interleukin 4 antagonist | |||
| 0.142 | 0.037 | 0.142 | TRPA1 agonist | |||
| 0.133 | 0.028 | 0.157 | Anabolic | 0.157 0.014 DBMET03096 | DBMET03096 | |
| 0.152 | 0.048 | 0.152 | Anesthetic local | |||
| 0.144 | 0.043 | 0.144 | Cystathionine beta-synthase inhibitor | |||
| 0.161 | 0.06 | 0.161 | Thiol protease inhibitor | |||
| 0.146 | 0.046 | 0.248 | Cholesterol synthesis inhibitor | 0.248 0.018 DBMET03096 | DBMET03096 | |
| 0.131 | 0.032 | 0.131 | GABA C receptor rho-1 antagonist | |||
| 0.099 | 0.004 | 0.099 | Glutamate (mGluR3) antagonist | |||
| 0.101 | 0.007 | 0.101 | Growth hormone secretagogue receptor antagonist | |||
| 0.107 | 0.013 | 0.107 | Beta 3 adrenoreceptor antagonist | |||
| 0.128 | 0.036 | 0.128 | Acetylcholine release stimulant | |||
| 0.098 | 0.008 | 0.098 | Beta 2 adrenoreceptor antagonist | |||
| 0.095 | 0.005 | 0.095 | Beta 2 adrenoreceptor agonist | 0.061 0.044 DBMET03096 | ||
| 0.11 | 0.025 | 0.194 | Keratolytic | 0.194 0.009 DBMET03096 | DBMET03096 | |
| 0.088 | 0.005 | 0.088 | Arginase inhibitor | |||
| 0.272 | 0.189 | 0.272 | Cyclophilin D inhibitor | |||
| 0.125 | 0.042 | 0.125 | Bronchodilator | |||
| 0.121 | 0.039 | 0.121 | HIV-1 integrase (Overall Integration) inhibitor | |||
| 0.1 | 0.018 | 0.256 | Biliverdin reductase inhibitor | 0.256 0.004 DBMET03096 | DBMET03096 | |
| 0.107 | 0.029 | 0.208 | Histidine decarboxylase inhibitor | 0.208 0.012 DBMET03096 | DBMET03096 | |
| 0.101 | 0.024 | 0.101 | Estrogen-related receptor beta agonist | |||
| 0.252 | 0.175 | 0.265 | Antibacterial | 0.265 0.164 DBMET03096 | DBMET03096 | |
| 0.084 | 0.008 | 0.084 | Adenosine deaminase inhibitor | 0.075 0.011 DBMET03096 | ||
| 0.087 | 0.012 | 0.087 | Glucosylceramidase inhibitor | |||
| 0.103 | 0.03 | 0.118 | Vanilloid agonist | 0.118 0.019 DBMET03096 | DBMET03096 | |
| 0.094 | 0.022 | 0.094 | GABA B receptor agonist | |||
| 0.105 | 0.034 | 0.246 | Porphobilinogen synthase inhibitor | 0.246 0.008 DBMET03096 | DBMET03096 | |
| 0.123 | 0.052 | 0.123 | Falcipain 3 inhibitor | |||
| 0.082 | 0.012 | 0.082 | Epithelial sodium channel blocker | |||
| 0.144 | 0.075 | 0.144 | Hemostatic | |||
| 0.117 | 0.049 | 0.117 | Carbonic anhydrase XV inhibitor | |||
| 0.079 | 0.011 | 0.079 | Growth hormone secretagogue receptor agonist | |||
| 0.087 | 0.02 | 0.087 | Glutamate (mGluR7) antagonist | |||
| 0.07 | 0.003 | 0.085 | Toll-Like receptor 8 agonist | 0.085 0.003 DBMET03096 | DBMET03096 | |
| 0.089 | 0.022 | 0.197 | Argininosuccinate synthase inhibitor | 0.197 0.008 DBMET03096 | DBMET03096 | |
| 0.09 | 0.024 | 0.09 | Cannabinoid CB1 receptor agonist | |||
| 0.076 | 0.011 | 0.149 | Lysophosphatidic acid 3 receptor antagonist | 0.149 0.003 DBMET03096 | DBMET03096 | |
| 0.23 | 0.167 | 0.23 | Toll-Like receptor 7 agonist | |||
| 0.263 | 0.201 | 0.318 | Apoptosis agonist | 0.318 0.159 DBMET03096 | DBMET03096 | |
| 0.079 | 0.018 | 0.079 | Glycine transporter 2 inhibitor | |||
| 0.069 | 0.008 | 0.102 | Geranyltranstransferase inhibitor | 0.102 0.003 DBMET03096 | DBMET03096 | |
| 0.145 | 0.085 | 0.145 | CF transmembrane conductance regulator agonist | |||
| 0.129 | 0.068 | 0.164 | Cyclooxygenase 3 inhibitor | 0.164 0.037 DBMET03096 | DBMET03096 | |
| 0.08 | 0.02 | 0.08 | Cannabinoid CB2 receptor antagonist | |||
| 0.062 | 0.003 | 0.153 | Lysophosphatidic acid receptor 1 agonist | 0.153 0.001 DBMET03096 | DBMET03096 | |
| 0.066 | 0.009 | 0.066 | Cytokine production stimulant | 0.046 0.041 DBMET03096 | ||
| 0.069 | 0.014 | 0.069 | Vanilloid 2 antagonist | |||
| 0.095 | 0.041 | 0.095 | Inducible nitric-oxide synthase inhibitor | |||
| 0.184 | 0.13 | 0.184 | Calpain inhibitor | |||
| 0.101 | 0.047 | 0.101 | Calcium antagonist | |||
| 0.069 | 0.015 | 0.069 | Leukotriene C antagonist | |||
| 0.1 | 0.046 | 0.1 | Histamine N-methyltransferase inhibitor | |||
| 0.067 | 0.014 | 0.121 | Glucose-6-phosphate isomerase inhibitor | 0.121 0.003 DBMET03096 | DBMET03096 | |
| 0.064 | 0.011 | 0.2 | Glutamate (mGluR group III) antagonist | 0.2 0.003 DBMET03096 | DBMET03096 | |
| 0.061 | 0.008 | 0.061 | Beta adrenoreceptor agonist | |||
| 0.106 | 0.054 | 0.277 | UDP-glucose 4-epimerase inhibitor | 0.277 0.011 DBMET03096 | DBMET03096 | |
| 0.07 | 0.019 | 0.07 | Aconitate hydratase inhibitor | |||
| 0.054 | 0.005 | 0.054 | Ceramide glucosyltransferase inhibitor | 0.036 0.023 DBMET03096 | ||
| 0.065 | 0.016 | 0.065 | Immunoglobulin Fc receptor antagonist | |||
| 0.069 | 0.02 | 0.069 | Leukotriene B4 antagonist | |||
| 0.06 | 0.012 | 0.06 | Plasmepsin II inhibitor | |||
| 0.087 | 0.039 | 0.165 | Glutamate dehydrogenase inhibitor | 0.165 0.014 DBMET03096 | DBMET03096 | |
| 0.115 | 0.07 | 0.115 | Proteasome inhibitor | |||
| 0.048 | 0.005 | 0.048 | Calcium-independent phospholipase A2 inhibitor | 0.036 0.018 DBMET03096 | ||
| 0.046 | 0.003 | 0.046 | Vanilloid 2 agonist | 0.038 0.004 DBMET03096 | ||
| 0.075 | 0.032 | 0.075 | NMDA receptor agonist | |||
| 0.053 | 0.011 | 0.053 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | |||
| 0.046 | 0.005 | 0.046 | Prostaglandin F2 alpha agonist | |||
| 0.047 | 0.005 | 0.047 | Glutamate (mGluR3) agonist | |||
| 0.097 | 0.056 | 0.097 | Bile acid receptor antagonist | |||
| 0.05 | 0.009 | 0.05 | Glutamate (mGluR8) antagonist | 0.04 0.017 DBMET03096 | ||
| 0.162 | 0.121 | 0.228 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.228 0.054 DBMET03096 | DBMET03096 | |
| 0.101 | 0.061 | 0.101 | Carbonic anhydrase III inhibitor | |||
| 0.176 | 0.137 | 0.176 | Nitric-oxide synthase stimulant | |||
| 0.048 | 0.009 | 0.296 | Lysophosphatidic acid 2 receptor antagonist | 0.296 0.002 DBMET03096 | DBMET03096 | |
| 0.051 | 0.013 | 0.051 | Kainate receptor agonist | |||
| 0.086 | 0.048 | 0.086 | Glycine receptor antagonist | 0.074 0.068 DBMET03096 | ||
| 0.131 | 0.094 | 0.131 | Acetylcholine M1 receptor antagonist | |||
| 0.049 | 0.013 | 0.089 | Glutamate (mGluR8) agonist | 0.089 0.004 DBMET03096 | DBMET03096 | |
| 0.146 | 0.111 | 0.146 | Lipocortins synthesis antagonist | |||
| 0.069 | 0.034 | 0.069 | Prostaglandin F2 alpha antagonist | |||
| 0.079 | 0.044 | 0.079 | Cathepsin G inhibitor | |||
| 0.08 | 0.046 | 0.08 | GABA aminotransferase inhibitor | |||
| 0.082 | 0.048 | 0.082 | Na+ K+ transporting ATPase inhibitor | |||
| 0.131 | 0.098 | 0.131 | Thrombolytic | |||
| 0.06 | 0.026 | 0.06 | Nicotinic alpha3beta2 receptor antagonist | |||
| 0.072 | 0.038 | 0.072 | Leukotriene antagonist | |||
| 0.046 | 0.014 | 0.046 | Leukotriene C4 antagonist | |||
| 0.048 | 0.017 | 0.048 | Membrane dipeptidase inhibitor | 0.046 0.019 DBMET03096 | ||
| 0.085 | 0.054 | 0.129 | Glutathione S-transferase inhibitor | 0.129 0.019 DBMET03096 | DBMET03096 | |
| 0.089 | 0.058 | 0.178 | NADH dehydrogenase inhibitor | 0.178 0.013 DBMET03096 | DBMET03096 | |
| 0.1 | 0.069 | 0.18 | Toll-Like receptor 4 antagonist | 0.18 0.01 DBMET03096 | DBMET03096 | |
| 0.104 | 0.073 | 0.104 | Mucolytic | 0.101 0.076 DBMET03096 | ||
| 0.049 | 0.019 | 0.049 | Angiotensin AT1 receptor antagonist | |||
| 0.064 | 0.033 | 0.064 | Gonadotropin-releasing hormone receptor agonist | |||
| 0.102 | 0.072 | 0.102 | Nav1.4 sodium channel blocker | |||
| 0.035 | 0.005 | 0.035 | Acid ceramidase inhibitor | |||
| 0.109 | 0.08 | 0.109 | Acetylcholine muscarinic antagonist | |||
| 0.051 | 0.023 | 0.051 | Neuraminidase (Influenza A) inhibitor | |||
| 0.063 | 0.035 | 0.117 | Ribonucleotide reductase inhibitor | 0.117 0.017 DBMET03096 | DBMET03096 | |
| 0.061 | 0.033 | 0.101 | Ribonucleoside-diphosphate reductase inhibitor | 0.101 0.019 DBMET03096 | DBMET03096 | |
| 0.04 | 0.012 | 0.04 | Adenosine uptake inhibitor | |||
| 0.067 | 0.04 | 0.067 | Protease 3C (Human rhinovirus) inhibitor | |||
| 0.045 | 0.018 | 0.045 | Kainate receptor 2 antagonist | |||
| 0.031 | 0.004 | 0.031 | Neuraminidase (Influenza B) inhibitor | |||
| 0.096 | 0.071 | 0.096 | Nav1.1 sodium channel blocker | |||
| 0.164 | 0.138 | 0.204 | Vasodilator | 0.204 0.102 DBMET03096 | DBMET03096 | |
| 0.054 | 0.029 | 0.137 | Antimetabolite | 0.137 0.013 DBMET03096 | DBMET03096 | |
| 0.038 | 0.014 | 0.038 | GHS receptor antagonist | |||
| 0.03 | 0.005 | 0.03 | Isoleucine-tRNA ligase inhibitor | |||
| 0.056 | 0.032 | 0.213 | Autotaxin inhibitor | 0.213 0.005 DBMET03096 | DBMET03096 | |
| 0.155 | 0.131 | 0.155 | Hypolipemic | |||
| 0.048 | 0.024 | 0.048 | Toll-Like receptor 2 agonist | |||
| 0.076 | 0.053 | 0.1 | Carbonic anhydrase XIII inhibitor | 0.1 0.038 DBMET03096 | DBMET03096 | |
| 0.04 | 0.017 | 0.089 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.089 0.004 DBMET03096 | DBMET03096 | |
| 0.047 | 0.024 | 0.047 | Histamine H2 receptor agonist | |||
| 0.027 | 0.004 | 0.084 | Lysophosphatidic acid receptor 3 agonist | 0.084 0.002 DBMET03096 | DBMET03096 | |
| 0.047 | 0.025 | 0.047 | Glutamate (mGluR4) antagonist | |||
| 0.041 | 0.019 | 0.041 | Nicotinic acid receptor agonist | |||
| 0.031 | 0.01 | 0.031 | Hedgehog signaling activator | |||
| 0.031 | 0.01 | 0.031 | Sodium/glucose cotransporter inhibitor | |||
| 0.063 | 0.043 | 0.063 | NMDA receptor glycine site agonist | |||
| 0.058 | 0.037 | 0.058 | Carbonic anhydrase VB inhibitor | |||
| 0.029 | 0.009 | 0.029 | Beta 1 adrenoreceptor agonist | |||
| 0.031 | 0.011 | 0.031 | Nicotinic acid receptor 2 antagonist | |||
| 0.06 | 0.04 | 0.06 | Carbonic anhydrase stimulant | |||
| 0.038 | 0.018 | 0.038 | Angiotensin II receptor antagonist | |||
| 0.036 | 0.016 | 0.036 | Prostaglandin agonist | |||
| 0.043 | 0.024 | 0.043 | Dopamine D5 agonist | |||
| 0.078 | 0.059 | 0.078 | Carbonic anhydrase VI inhibitor | |||
| 0.082 | 0.063 | 0.082 | Myeloperoxidase inhibitor | |||
| 0.031 | 0.012 | 0.031 | Sodium/glucose cotransporter 2 inhibitor | |||
| 0.051 | 0.032 | 0.051 | Bombesin 2 receptor antagonist | |||
| 0.032 | 0.014 | 0.032 | Purinergic P2Y15 antagonist | |||
| 0.091 | 0.073 | 0.091 | Electrolyte absorption antagonist | |||
| 0.074 | 0.057 | 0.074 | Nicotinic alpha4beta2 receptor antagonist | |||
| 0.049 | 0.033 | 0.049 | Dopamine beta hydroxylase inhibitor | |||
| 0.054 | 0.039 | 0.054 | Thromboxane synthase inhibitor | |||
| 0.039 | 0.025 | 0.039 | Glutamate (mGluR group II) antagonist | |||
| 0.043 | 0.029 | 0.043 | Oxytocin agonist | |||
| 0.082 | 0.069 | 0.082 | Interleukin 5 antagonist | |||
| 0.04 | 0.027 | 0.04 | AMPA 4 receptor antagonist | |||
| 0.06 | 0.049 | 0.06 | Histone deacetylase SIRT3 inhibitor | |||
| 0.115 | 0.104 | 0.115 | Nav1.6 sodium channel blocker | |||
| 0.033 | 0.023 | 0.033 | Carboxypeptidase B inhibitor | |||
| 0.015 | 0.005 | 0.015 | Calcium-dependent phospholipase A2 inhibitor | |||
| 0.035 | 0.025 | 0.105 | Phosphoglycerate kinase inhibitor | 0.105 0.006 DBMET03096 | DBMET03096 | |
| 0.102 | 0.092 | 0.102 | Cholinergic antagonist | |||
| 0.024 | 0.015 | 0.024 | Prostaglandin EP2 agonist | |||
| 0.019 | 0.01 | 0.019 | Ileal bile acid transport inhibitor | |||
| 0.017 | 0.008 | 0.017 | Thromboxane A2 agonist | |||
| 0.176 | 0.168 | 0.176 | Neuropeptide Y2 antagonist | |||
| 0.071 | 0.063 | 0.071 | Vanilloid 4 agonist | |||
| 0.018 | 0.01 | 0.018 | Carbonic anhydrase VIII inhibitor | |||
| 0.018 | 0.01 | 0.018 | Carbonic anhydrase X inhibitor | |||
| 0.1 | 0.093 | 0.1 | Acetylcholine antagonist | |||
| 0.031 | 0.024 | 0.031 | Dipeptidyl peptidase II inhibitor | |||
| 0.056 | 0.049 | 0.119 | Purinergic P2X1 antagonist | 0.119 0.012 DBMET03096 | DBMET03096 | |
| 0.065 | 0.059 | 0.065 | Secretase beta inhibitor | |||
| 0.026 | 0.019 | 0.026 | Lysine carboxypeptidase inhibitor | |||
| 0.027 | 0.02 | 0.027 | Leukotriene B4 receptor 1 antagonist | |||
| 0.028 | 0.022 | 0.028 | 1,3-Beta-glucan synthase inhibitor | |||
| 0.035 | 0.029 | 0.035 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | |||
| 0.032 | 0.027 | 0.065 | Fumarate hydratase inhibitor | 0.065 0.009 DBMET03096 | DBMET03096 | |
| 0.058 | 0.053 | 0.058 | Neutrophil collagenase inhibitor | |||
| 0.026 | 0.021 | 0.039 | Uridine phosphorylase inhibitor | 0.039 0.012 DBMET03096 | DBMET03096 | |
| 0.048 | 0.044 | 0.048 | Neuropeptide agonist | |||
| 0.011 | 0.007 | 0.011 | Thromboxane agonist | |||
| 0.044 | 0.041 | 0.044 | Thromboxane A2 antagonist | |||
| 0.055 | 0.052 | 0.055 | Glucagon-like peptide 1 agonist | |||
| 0.018 | 0.014 | 0.018 | Estrogen-related receptor gamma agonist | |||
| 0.046 | 0.042 | 0.046 | NMDA 2A receptor antagonist | |||
| 0.012 | 0.009 | 0.032 | Glutamate (mGluR6) agonist | 0.032 0.003 DBMET03096 | DBMET03096 | |
| 0.027 | 0.024 | 0.027 | Estrogen-related receptor gamma antagonist | |||
| 0.016 | 0.014 | 0.016 | Nicotinic acid receptor 1 antagonist | |||
| 0.047 | 0.045 | 0.047 | Thromboxane antagonist | |||
| 0.031 | 0.029 | 0.031 | Melatonin receptor 1A agonist | |||
| 0.079 | 0.077 | 0.079 | Granulocyte macrophage colony stimulating factor agonist | |||
| 0.026 | 0.024 | 0.026 | Baculoviral IAP repeat-containing protein 4 inhibitor | |||
| 0.053 | 0.051 | 0.053 | Bombesin 1 receptor agonist | |||
| 0.087 | 0.085 | 0.101 | Expectorant | 0.101 0.067 DBMET03096 | DBMET03096 | |
| 0.122 | 0.121 | 0.122 | GABA C receptor rho-2 antagonist | |||
| 0.05 | 0.049 | 0.12 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.12 0.011 DBMET03096 | DBMET03096 | |
| 0.029 | 0.028 | 0.029 | ATP citrate lysase inhibitor | |||
| 0.029 | 0.028 | 0.029 | Calcitonin receptor agonist | |||
| 0.014 | 0.015 | 0.024 | Purinergic P2Y1 agonist | 0.024 0.005 DBMET03096 | DBMET03096 | |
| 0.053 | 0.057 | 0.06 | Lipocortins synthesis agonist | 0.06 0.035 DBMET03096 | DBMET03096 | |
| 0.018 | 0.022 | 0.055 | Lysophosphatidic acid 1 receptor antagonist | 0.055 0.004 DBMET03096 | DBMET03096 | |
| 0.064 | 0.069 | 0.093 | CDC25A inhibitor | 0.093 0.032 DBMET03096 | DBMET03096 | |
| 0.189 | 0.195 | 0.196 | Apoptosis antagonist | 0.196 0.185 DBMET03096 | DBMET03096 | |
| 0.087 | 0.095 | 0.178 | Folate antagonist | 0.178 0.014 DBMET03096 | DBMET03096 | |
| 0.051 | 0.059 | 0.055 | Cathepsin E inhibitor | 0.055 0.048 DBMET03096 | DBMET03096 | |
| 0.144 | 0.152 | 0.18 | Platelet antagonist | 0.18 0.117 DBMET03096 | DBMET03096 | |
| 0.034 | 0.043 | 0.062 | Thymidine kinase inhibitor | 0.062 0.013 DBMET03096 | DBMET03096 | |
| 0.004 | 0.016 | 0.042 | Mannitol 2-dehydrogenase inhibitor | 0.042 0.001 DBMET03096 | DBMET03096 | |
| 0.075 | 0.088 | 0.21 | Aminoacyl-tRNA synthetase inhibitor | 0.21 0.01 DBMET03096 | DBMET03096 | |
| 0.021 | 0.034 | 0.049 | Squalene synthetase inhibitor | 0.049 0.015 DBMET03096 | DBMET03096 | |
| 0.008 | 0.023 | 0.011 | Purine nucleoside phosphorylase inhibitor | 0.011 0.008 DBMET03096 | DBMET03096 | |
| 0.028 | 0.045 | 0.051 | Growth factor receptor-bound protein 2 antagonist | 0.051 0.004 DBMET03096 | DBMET03096 | |
| 0.015 | 0.034 | 0.019 | Methylmalonyl-CoA mutase inhibitor | 0.019 0.01 DBMET03096 | DBMET03096 | |
| 0.034 | 0.056 | 0.055 | AICAR transformylase inhibitor | 0.055 0.018 DBMET03096 | DBMET03096 | |
| 0.044 | 0.067 | 0.068 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.068 0.032 DBMET03096 | DBMET03096 | |
| 0.073 | 0.098 | 0.111 | Hematopoietic | 0.111 0.027 DBMET03096 | DBMET03096 | |
| 0.03 | 0.067 | 0.064 | Fructose-1,6-bisphosphatase inhibitor | 0.064 0.015 DBMET03096 | DBMET03096 | |
| 0.124 | 0.161 | 0.132 | Heat shock protein 70 antagonist | 0.132 0.11 DBMET03096 | DBMET03096 | |
| 0.043 | 0.082 | 0.065 | Carbonic anhydrase V inhibitor | 0.065 0.047 DBMET03096 | DBMET03096 | |
| 0.07 | 0.109 | 0.09 | D-Ala-D-Ala ligase inhibitor | 0.09 0.044 DBMET03096 | DBMET03096 | |
| 0.078 | 0.123 | 0.132 | Glutamate (mGluR7) agonist | 0.132 0.02 DBMET03096 | DBMET03096 | |
| 0.009 | 0.057 | 0.028 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.028 0.019 DBMET03096 | DBMET03096 | |
| 0.019 | 0.07 | 0.051 | Toll-Like receptor 4 agonist | 0.051 0.004 DBMET03096 | DBMET03096 | |
| 0.013 | 0.065 | 0.026 | Urotensin II agonist | 0.026 0.02 DBMET03096 | DBMET03096 | |
| 0.09 | 0.143 | 0.127 | Transcription factor STAT6 inhibitor | 0.127 0.049 DBMET03096 | DBMET03096 | |
| 0.065 | 0.121 | 0.082 | Transcription factor NF kappa B stimulant | 0.082 0.065 DBMET03096 | DBMET03096 | |
| 0.042 | 0.108 | 0.057 | Adenine nucleotide translocase inhibitor | 0.057 0.034 DBMET03096 | DBMET03096 | |
| 0.067 | 0.136 | 0.145 | Adenylate cyclase inhibitor | 0.145 0.048 DBMET03096 | DBMET03096 | |
| 0.003 | 0.081 | 0.028 | Purinergic P2Y agonist | 0.028 0.004 DBMET03096 | DBMET03096 | |
| 0.003 | 0.085 | 0.035 | Purinergic P2 agonist | 0.035 0.004 DBMET03096 | DBMET03096 | |
| 0.003 | 0.085 | 0.035 | Purinergic receptor agonist | 0.035 0.004 DBMET03096 | DBMET03096 | |
| 0.008 | 0.095 | 0.025 | Purinergic P2Y12 antagonist | 0.025 0.014 DBMET03096 | DBMET03096 | |
| 0.027 | 0.117 | 0.182 | Purinergic P2X2 antagonist | 0.182 0.006 DBMET03096 | DBMET03096 | |
| 0.035 | 0.152 | 0.071 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.071 0.06 DBMET03096 | DBMET03096 | |
| 0.013 | 0.13 | 0.083 | Purinergic P2Y antagonist | 0.083 0.012 DBMET03096 | DBMET03096 | |
| 0.053 | 0.174 | 0.115 | Chelator | 0.115 0.058 DBMET03096 | DBMET03096 | |
| 0.007 | 0.134 | 0.078 | Purinergic P2X agonist | 0.078 0.004 DBMET03096 | DBMET03096 | |
| 0.006 | 0.146 | 0.031 | Inosine monophosphate dehydrogenase 1 inhibitor | 0.031 0.008 DBMET03096 | DBMET03096 | |
| 0.077 | 0.228 | 0.185 | Hexokinase inhibitor | 0.185 0.045 DBMET03096 | DBMET03096 | |
| 0.066 | 0.269 | 0.17 | Mannose-6-phosphate isomerase inhibitor | 0.17 0.049 DBMET03096 | DBMET03096 | |
| 0.025 | 0.248 | 0.094 | Potassium channel (Ca-activated) blocker | 0.094 0.011 DBMET03096 | DBMET03096 | |
| 0.028 | 0.296 | 0.065 | Potassium channel large-conductance Ca-activated activator | 0.065 0.05 DBMET03096 | DBMET03096 | |
| 0.082 | 0.37 | 0.212 | Transcription factor STAT3 inhibitor | 0.212 0.12 DBMET03096 | DBMET03096 | |
| 0.067 | 0.428 | 0.207 | Transcription factor STAT inhibitor | 0.207 0.128 DBMET03096 | DBMET03096 | |
| 0.077 | 0.451 | 0.158 | Catenin beta inhibitor | 0.158 0.088 DBMET03096 | DBMET03096 | |
| 0.009 | 0.557 | 0.087 | Purinergic P2Y2 antagonist | 0.087 0.005 DBMET03096 | DBMET03096 | |
| 0.005 | 0.669 | 0.067 | Purinergic P2 antagonist | 0.067 0.041 DBMET03096 | DBMET03096 | |
| 0.003 | 0.786 | 0.034 | Purinergic P2Y1 antagonist | 0.034 0.005 DBMET03096 | DBMET03096 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |